MedTrace Logo

Evaluation of Safety and Tolerability of Libella Gene Therapy for the Treatment of Aging: AAV- hTERT

NCT04133649 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2019-12-10

No results posted yet for this study

Summary

Using gene therapy to express active telomerase (hTERT) in humans has the potential to treat many of the age related diseases, including Aging itself.

This study will entail treating subjects with hTERT delivered via transduction using AAV. The goal is to extend the telomeres to prevent, delay, or even reverse Aging.

Conditions

  • Aging

Interventions

DRUG

AAV-hTERT

subjects will receive a single LGT (AAV-hTERT) treatment via IV administration

Sponsors & Collaborators

  • Libella Gene Therapeutics

    lead INDUSTRY

Principal Investigators

  • Winston Pernet, MD · IPS Arcaslud SAS

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-17
Primary Completion
2021-01-31
Completion
2021-01-31

Countries

  • Colombia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04133649 on ClinicalTrials.gov